October 31, 2014
Sumitomo Dainippon Pharma registered lackluster sales in April-September as the NHI drug price revision in April wreaked havoc on its Japan sales, overshadowing bullish sales of its antipsychotic Latuda (lurasidone) in the US. The Japanese drug maker said on October...read more